Trial Profile
A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs H4IC (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aeras
- 12 Jul 2018 Results published in the New England Journal of Medicine
- 09 Jul 2018 Results published in the Aeras Media Release
- 09 Jul 2018 According to an Aeras media release, Final results from this study published in the New England Journal of Medicine (NEJM).